Brief: Plus Therapeutics Completes Dosing In Cohort 5 Of Phase 1 Trial Of Rhenium Obisbemeda In Leptomeningeal Metastases
11/03/2024 11:45
March 11 (Reuters) - Plus Therapeutics Inc PSTV.O :
* PLUS THERAPEUTICS COMPLETES DOSING IN COHORT 5 OF
RESPECT-LM
PHASE 1 TRIAL OF RHENIUM (186RE) OBISBEMEDA IN LEPTOMENINGEAL
METASTASES
* PLUS THERAPEUTICS INC - ANTICIPATES MOVING INTO COHORT 6
IN Q2
2024 FOLLOWING STANDARD SAFETY REVIEW
Source text for Eikon: ID:nGNX7H1bDg
Further company coverage: PSTV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer